Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
Rhea-AI Summary
Propanc Biopharma (Nasdaq:PPCB) approved a 1-for-25 reverse stock split of its common shares, effective before market open on May 18, 2026. The split will proportionally reduce outstanding shares, with fractional shares rounded up, and will not change the par value.
The stock will continue trading on Nasdaq under the symbol PPCB with a new CUSIP 74346N800. Propanc states the reverse split is intended to help restore compliance with Nasdaq’s $1.00 minimum bid price and support its growth plans.
AI-generated analysis. Not financial advice.
Positive
- 1-for-25 reverse stock split designed to help regain Nasdaq $1.00 bid compliance
- Fractional shares rounded up to nearest whole share per shareholder
- Trading symbol PPCB maintained post-split, aiding investor continuity
- Par value of common stock unchanged after reverse split
Negative
- Need to restore compliance with Nasdaq continued listing and $1.00 bid standards signals prior noncompliance risk
News Market Reaction – PPCB
On the day this news was published, PPCB declined 21.40%, reflecting a significant negative market reaction. Argus tracked a peak move of +10.5% during that session. Argus tracked a trough of -24.4% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $565K from the company's valuation, bringing the market cap to $2.08M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
PPCB showed a modest pre-news move while momentum peers were mixed: CRIS up 6.94%, ICU up 5.67%, and RNTX down 2.24%. Divergent peer directions and no same-day peer news suggest the reverse split is a stock-specific catalyst rather than a sector-wide biotech move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 24 | Research partnership | Positive | -5.9% | Multi-year anti-aging and cancer research collaboration with Spanish universities. |
| Mar 12 | Preclinical results | Positive | -13.6% | Reported >85% tumor inhibition and plans for Phase 1b trials in 2026. |
| Mar 10 | Service agreement | Positive | -20.5% | Service deal to develop LC-MS PK assay supporting Phase 1b study of PRP. |
| Mar 03 | Pipeline update | Positive | -5.2% | Detailed PRP preclinical efficacy, orphan status and planned 2026 first-in-human trial. |
| Feb 18 | Corporate update | Positive | -4.5% | Half-year results, IP expansion plans, and up to $100M private placement facility. |
Recent PPCB news on partnerships, preclinical data, and corporate updates has been followed by negative 24-hour price reactions despite generally positive operational tone.
Over the last few months, PPCB announced multiple developments around its lead asset PRP and broader research platform. A March 2026 collaboration with Spanish universities expanded anti-aging and cancer research efforts. Several releases highlighted strong preclinical tumor inhibition data and preparations for a planned Phase 1b first‑in‑human study. A February corporate update detailed growing IP and financing facilities. Despite these seemingly constructive steps, each event saw share price declines, framing today’s reverse split within a backdrop of market skepticism.
Market Pulse Summary
The stock dropped -21.4% in the session following this news. A negative reaction despite the corporate rationale would fit PPCB’s pattern of declines following ostensibly constructive updates. The 1-for-25 reverse split, reduction of outstanding shares to about 2.28M, and focus on Nasdaq’s $1.00 bid standard highlight listing pressure and prior dilution. Investors would need to weigh whether future financings and preclinical-to-clinical execution could further pressure post-split pricing.
Key Terms
reverse stock split financial
par value financial
nasdaq regulatory
cusip regulatory
phase 1b medical
AI-generated analysis. Not financial advice.
MELBOURNE, Australia , May 13, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced that its Board of Directors on March 16, 2026, approved a 1-for-25 reverse stock split of the Company's issued and outstanding shares of common stock, par value
As a result of the Reverse Stock Split, every 25 pre-split shares of Company common stock outstanding will automatically combine into one new share of common stock without any action on the part of the holders, and the number of outstanding common shares will be reduced from approximately 56,959,280 million shares (as of May 6, 2026) to approximately 2,278,372 million shares on a pro forma basis. Fractional shares resulting from the Reverse Stock Split will be rounded up to the nearest whole share on a per shareholder basis (per participant basis at DTC). The Reverse Stock Split will not affect the par value of the Company’s common stock.
The Company anticipates that the effective time of the Reverse Stock Split will be before market open on May 18, 2026, with the common stock trading on a post-split basis under the Company's existing trading symbol, “PPCB,” with a new CUSIP number, 74346N800. Securities Transfer Corporation, the Company’s transfer agent, will act as the exchange agent for the Reverse Stock Split.
“The Reverse Stock Split is being implemented to enable the Company to expeditiously restore compliance with the continued listing standards of the Nasdaq Stock Market and Nasdaq’s
About Propanc Biopharma, Inc.
Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The Company’s lead product candidate, PRP, is designed to address the underlying drivers of cancer proliferation and spread.
More information: www.propanc.com
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of several factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.
Company:
Propanc Biopharma, Inc.
James Nathanielsz
+61-3-9882-0780
Investor Contact:
